Gisele Vajgel

Gisele Vajgel


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
COCamila Barbosa Lyra Oliveira
Camila Barbosa Lyra Oliveira
CLCamilla de Lima
Camilla de Lima
GVGisele Vajgel
Gisele Vajgel
PSPAULA SANDRIN-GARCIA
PAULA SANDRIN-GARCIA
Lupus nephritis (LN) is the most frequent and severe of systemic lupus erythematosus (SLE) clinical manifestations and contributes to the increase of morbidity and mortality of patients due to chronic kidney disease. The NLRP3 (NLR pyrin domain containing 3) is a member of the NLR (NOD-like receptors), and its activation results in the production of pro-inflammatory cytokines, which can contribute to the pathogenesis of LN. In this review manuscript, we approach the relation between the NLRP3 inflammasome, SLE, and LN, highlighting the influence of genetic susceptibility of NLRP3 polymorphisms in the disease; the main functional studies using cellular and animal models of NLRP3 activation; and finally, some mechanisms of NLRP3 inhibition for the development of possible therapeutic drugs for LN.

15 November 2019 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
GVGisele Vajgel
Gisele Vajgel
SLSuelen Cristina Lima
Suelen Cristina Lima
DSDiego Jeronimo S. Santana
Diego Jeronimo S. Santana
COCamila Barbosa Lyra Oliveira
Camila Barbosa Lyra Oliveira
DCDenise Maria N. Costa
Denise Maria N. Costa
PSPaula Sandrin-Garcia
Paula Sandrin-Garcia
Objective.: Apolipoprotein L1 gene (APOL1) G1 and G2 renal risk alleles (RRA) are associated with endstage renal disease in blacks with lupus nephritis (LN). The present study determined frequencies ofAPOL1RRA in nonwhite Brazilian patients with LN and controls to assess association with renal outcomes.Methods.: APOL1 RRA were genotyped in 222 healthy blood donors (controls) and 201 cases with LN from 3 outpatient clinics. Two single-nucleotide polymorphisms in the G1 (rs73885319 and rs60910145) and an indel for the G2 (rs71785313) variant were genotyped.Results.: The frequency ofAPOL1RRA in nonwhite Brazilian LN cases did not differ significantly from healthy controls, and few participants had 2 RRA. In the sample, 84.6% of LN cases and 84.2% of controls had 0 RRA, 13.4% and 15.3% had 1 RRA, and 2.0% and 0.4% had 2 RRA, respectively. LN cases with ≥ 1APOL1RRA had similar baseline characteristics and renal responses to treatment, yet faced higher risk for progressive chronic kidney disease (CKD) to an estimated glomerular filtration rate < 30 ml/min/1.73 m2compared to those with 0 RRA (11.2% with 0, 29.6% with 1; 50% with 2 RRA, p = 0.005). Although glomerular lesions and activity scores on initial kidney biopsy did not differ significantly between individuals based onAPOL1genotype, chronicity scores, tubular atrophy, and interstitial fibrosis were more severe in those with ≥ 1 RRA (p = 0.011, p = 0.002, p = 0.018, respectively).Conclusion.: Although initial kidney lesions and treatment responses were similar, a singleAPOL1RRA in nonwhite Brazilians with LN was associated with increased risk of advanced CKD and possibly more tubulointerstitial damage.

4 December 2019 in Lupus
Verified
Journal Article
Closed access
PDF file
GVGisele Vajgel
Gisele Vajgel
COCamila Barbosa Lyra Oliveira
Camila Barbosa Lyra Oliveira
DCD M N Costa
D M N Costa
MCM A G M Cavalcante
M A G M Cavalcante
LVL M Valente
L M Valente
PSP Sandrin-Garcia
P Sandrin-Garcia
Objective: We analyzed baseline and follow-up characteristics related to poorer renal outcomes in a Brazilian cohort of admixture race patients with lupus nephritis. Methods: Overall, 280 outpatients with a diagnosis of systemic lupus erythematosus and previous kidney biopsy of lupus nephritis were recruited from August 2015 to December 2018 and had baseline laboratory and histologic data retrospectively analyzed; patients were then followed-up and data were recorded. The main outcome measure was the estimated glomerular filtration rate at last follow-up. Secondary analyses assessed the impact of initial kidney histology and treatment in long-term kidney survival. Results: Median duration of lupus nephritis was 60 months (interquartile range: 27–120); 40 (14.3%) patients presented progressive chronic kidney disease (estimated glomerular filtration rate <30 and ≥10 ml/min/1.73 m2) or end-stage kidney disease at last visit. Adjusted logistic regression analysis showed that class IV lupus nephritis (odds ratio 14.91; 95% confidence interval 1.77–125.99; p = 0.01) and interstitial fibrosis ≥25% at initial biopsy (odds ratio 5.87; 95% confidence interval 1.32–26.16; p = 0.02), lack of complete or partial response at 12 months (odds ratio 16.3; 95% confidence interval 3.74–71.43; p < 0.001), and a second renal flare (odds ratio 4.49; 95% confidence interval 1.10–18.44; p = 0.04) were predictors of progressive chronic kidney disease. In a Kaplan-Meier survival curve we found that class IV lupus nephritis and interstitial fibrosis ≥25% were significantly associated with end-stage kidney disease throughout follow-up (hazard ratio 2.96; 95% confidence interval 1.3–7.0; p = 0.036 and hazard ratio 4.96; 95% confidence interval 1.9–12.9; p < 0.0001, respectively). Conclusion: In this large cohort of admixture race patients, class IV lupus nephritis and chronic interstitial damage at initial renal biopsy together with non-response after 1 year of therapy and relapse were associated with worse long-term renal outcomes.

1 December 2025 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
GVGisele Vajgel
Gisele Vajgel
BJBraziliano Miguel da Silva Júnior
Braziliano Miguel da Silva Júnior
CFCarlos R Silva Miranda Filho
Carlos R Silva Miranda Filho
COCamila Barbosa Lyra Oliveira
Camila Barbosa Lyra Oliveira
DCDenise Maria Do Nascimento Costa
Denise Maria Do Nascimento Costa
PSPaula Sandrin-Garcia
Paula Sandrin-Garcia
Background: Lupus nephritis (LN) patients under immunosuppression were excluded from the main trials with sodium–glucose co-transporter 2 inhibitors. This trial aims to analyse the effect and safety of dapagliflozin in inactive LN patients with residual proteinuria. Methods: We recruited adult LN patients (class III, IV(±V)] without activity, with proteinuria >500 mg/24 h and an estimated glomerular filtration rate (eGFR) ≥20 ml/min, on maintenance treatment with stable renin–angiotensin–aldosterone system inhibitors and mycophenolate mofetil ≤2 g/day. They were randomized to receive dapagliflozin on top of standard-of-care (SoC) therapy or not. After 6 months the groups were crossed over. The primary endpoint is a reduction of proteinuria compared with baseline (6 and 12 months). Results: From 97 screened patients, we excluded 67 due to active LN, low proteinuria or low eGFR. Thirty patients were randomized: 14 to start the treatment with dapagliflozin on top of SoC therapy and 16 to remain with the usual therapy for 6 months. Nine patients were excluded from the analysis due to new LN flares or lost to follow-up. The mean age was 40.6 ± 12.3 years, 19 (90.5%) were female, none had diabetes and the mean body mass index was 26.1 ± 5.2. The final analysis showed a significant reduction in proteinuria of −36.1% in patients after 6 months of dapagliflozin as opposed to −3.5% for those in the SoC therapy group (P = .03). There were more reported hypotension symptoms in the dapagliflozin group [7 cases (33.3%)] but no drug withdrawal and no significant changes in blood pressure or weight in the follow-up between the groups. There was one case of urinary infection in each group, but in the same patient. Conclusions: We demonstrate a significant reduction in residual proteinuria in patients with inactive LN with dapagliflozin without safety concerns.

1 January 2026 in Brazilian Journal of Nephrology
Verified
Journal Article
Open access
VCViviane Calice-Silva
Viviane Calice-Silva
PAPatrícia Abreu
Patrícia Abreu
MPMaria Eliete Pinheiros
Maria Eliete Pinheiros
ALAna Katarina de Cerqueira Delgado Lopes
Ana Katarina de Cerqueira Delgado Lopes
KPKarla Cristina Petruccelli
Karla Cristina Petruccelli
José A. Moura-NetoJosé A. Moura-Neto
José A. Moura-Neto
Introduction: Chronic kidney disease (CKD) is a public health issue, with an estimated prevalence of 10% in Brazil, possibly underestimated due to regional inequalities and diagnostic limitations. The EPI-CKD Brazil study aimed to estimate the prevalence of estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 in adults with risk factor for CKD, using point-of-care creatinine testing (POCTcr) during World Kidney Day 2025, and to assess regional variations and associated predictors. Methods: We conducted a multicenter cross-sectional study across 20 state chapters of the Brazilian Society of Nephrology, including individuals ≥ 18 years with at least one CKD risk factor (age > 60 years, hypertension [HTN], diabetes mellitus [DM], cardiovascular disease, obesity, chronic use of nonsteroidal anti-inflammatory drugs, history of acute kidney injury, bilateral kidney stones, or family history of CKD). Renal function was assessed using a rapid creatinine test (NovaMaxPro®–eGFR CKD-EPI 2021). Reduced eGFR was defined as < 60 mL/min/1.73 m2. Results: We analyzed 8,374 participants (66.9% women; median age, 58 years; BMI, 28.3 kg/m2; 46.2% mixed race). The frequency of reduced eGFR was 40.2% (n = 3,370), of whom 36% were in stages G3b–G5. Only 35.2% were aware of CKD risk factors. Significant regional differences were observed (ranging from 27.9% [Bahia] to 55.2% [Paraná]; p < 0.001). Independent predictors included age (OR = 1.032; 95%CI: 1.028–1.035), HTN (OR = 1.27; 95%CI: 1.15–1.40), and indigenous ethnicity as a protective factor (OR = 0.40; 95%CI: 0.20–0.89; p < 0.05). Risk increased by 23% for each additional risk factor. Conclusion: A high frequency of reduced eGFR and low awareness of CKD risk factors were observed. The study demonstrates the feasibility of POCTcr in screening strategies and reinforces the need for public policies to expand early diagnosis and strengthen primary care.

Verified
Journal Article
Open access
PDF file
COCamila Barbosa Lyra Oliveira
Camila Barbosa Lyra Oliveira
WGWerbson Lima Guaraná
Werbson Lima Guaraná
GVGisele Vajgel
Gisele Vajgel
BJBraziliano Miguel da Silva Júnior
Braziliano Miguel da Silva Júnior
CLCamilla Albertina Dantas de Lima
Camilla Albertina Dantas de Lima
PSPAULA SANDRIN-GARCIA
PAULA SANDRIN-GARCIA
Lupus nephritis (LN) can affect up to 60% of patients with systemic lupus erythematosus (SLE). The NLRP3 inflammasome has been implicated in the pathogenesis of LN. This study aimed to evaluate the role of the NLRP3 inflammasome as a predictor of response to immunosuppressive treatment in patients with active LN. A prospective cohort study was conducted with 20 adult patients with active LN, classes III, IV, and V, from January 2021 to September 2023. Patients were followed up at biopsy (T0) and 6 months (T6) and 12 months (T12) after treatment and classified according to the primary efficacy renal response (PERR) at 12 months. Gene expression of NLRP3, CARD8, CASP1, IL1B, and IL18 was evaluated by RT-qPCR in PBMCs. Immunohistochemistry (IHC) for NLRP3 was performed on kidney tissue. The concentration of cytokine IL-1β was measured using the BD™ Cytometric Bead Array (CBA). The mean age was 31.9 ± 8.3 years, with 19 females and 1 male. After 12 months, 65% of patients achieved PERR. The IHC intensity in inflammatory cells was higher in patients with no PERR (p = 0.0426). In the no-PERR group, the gene expression of IL1B showed a significant increase at T6 (FC = 2.22: p = 0.0037) and T12 (FC = 2.91; p = 0.0001) compared with T0. Relative expression of IL1B was higher in no-PERR patients at T12 compared to the PERR group (p = 0.0477). The no-PERR group also had higher serum IL-1β levels compared to the PERR group at 12 months (2.9 ± 0.5 vs. 2.5 ± 0.7, p = 0.0164). In conclusion, our study evidenced an increase in IL1B expression and IL-1β levels over the 12 months of treatment in no-PERR patients, suggesting a potential biomarker of disease activity. Furthermore, a strong NLRP3 IHC staining score was associated with a higher likelihood of no PERR, highlighting the potential of the NLRP3 inflammasome as a predictor of worse clinical outcomes.